INTRODUCTION {#S1}
============

Non-tuberculous mycobacteria (NTM) are a group of opportunistic pathogens which are being increasingly recognized as a cause of infection \[[@ref1]\]. They are also environmental organisms that can be found in many different ecosystems without public health implications \[[@ref2]\].

NTM infections are an emerging phenomenon, mainly in the last decade \[[@ref3]\]. It has been observed an increasing importance of infections caused by these organisms, both localized and disseminated, including also outbreaks and pseudo-outbreaks \[[@ref4]-[@ref5]\]. Among these, non-pigmented rapidly growing mycobacteria (NPRGM) are ubiquitous in nature and widely distributed in water, soil and animals \[[@ref2], [@ref6]\].

The three most important species of this group, regarding their clinical relevance, are *Mycobacterium fortuitum*, *Mycobacterium chelonae* and *Mycobacterium abscessus* \[[@ref7]\]. However, there are many other species capable of causing human diseases such as *Mycobacterium mucogenicum*, *Mycobacterium immunogenum*, *Mycobacterium goodii*, *Mycobacterium peregrinum*, *Mycobacterium phocaium*, *Mycobacterium porcinum*, *Mycobacterium smegmatis* or *Mycobacterium wolinskyi* \[[@ref7]-[@ref9]\].

These microorganisms have the ability to form biofilms and this gives these organisms many advantages over the planktonic type of growth, as resistance to environmental aggressions and an increased resistance against disinfectants and antibiotics \[[@ref10]\].

*M. abscessus* is one of the most frequently causative agents of nontuberculous mycobacterial pulmonary disease, often isolated in patients with underlying chronic lung diseases, like old tuberculosis scars, silicosis, bullae and other lung cavities where NTM can develop a biofilm. In recent times, patients with chronic bronchiectasis and cystic fibrosis have been found to be a target for NPRGM infections \[[@ref11]-[@ref13]\].

*M. chelonae* and *M. fortuitum* are frequently isolated in skin and soft tissue infections \[[@ref14]-[@ref15]\]. However, all these organisms can be isolated in other different clinical samples as a cause of many types of infection.

Here we report our experience with the diseases caused by these organisms isolated in our hospital during a 13-year period in order to compare these results with previous studies regarding these organisms.

MATERIAL AND METHODS {#S2}
====================

A retrospective study was performed to evaluate the clinical significance of the NPRGM. For this purpose, records dating from January 1^st^ 2004 to December 31^st^ 2017 from the mycobacteriology laboratory of the clinical microbiology department were reviewed. Patients with at least one isolate of NPRGM from clinical samples were selected for clinical charts review.

Sample processing and identification of bacterial isolates was performed following the internationally accepted protocols. The decontamination technique for all samples was the N-acetyl-cysteine-NaOH protocol throughout all these years. After decontamination, all samples were inoculated onto Lowenstein-Jensen and Coletsos solid slants and were inoculated also in a liquid medium (MGIT 960 from 2004 to 2009, from BD, USA, VERSATREK (Biomérieux, France) from 2009 to 2016 and BacT/ALERT 3D (Biomérieux, France) from 2016 to date.

Mycobacterial isolates were identified using a commercial PCR identification test (GenoType CM/AS, Hain, Germany), and those isolates that could not be identified with this technique were sent to the Mycobacteria reference laboratory (Centro Nacional de Microbiología, Majadahonda, Spain). Antimicrobial susceptibility test was performed for all mycobacterial isolates with the broth microdilution reference technique \[[@ref16]\].

On one hand, clinical charts were evaluated according to a predefined protocol that includes demographics, evaluation of risk factors (respiratory syndromes, HIV infection, immunosuppressive drug treatment and presence of biomaterials), clinical syndrome, treatment and outcome. Criteria from the ATS \[[@ref17]\] for interpretation of an isolate were followed to determine the clinical significance of each case. On the other hand, we considered a case of doubtful clinical significance when it presented with clinical signs of infection in the absence of other possible causes, and showed improvement after treatment with antimicrobial therapy, but did not fulfill the microbiological criteria. The Clinical Research Ethics Committee of our hospital approved the study (registration number EO137-18_FJD)

RESULTS {#S3}
=======

Growing of NPRGM was observed in 76 clinical samples of 59 patients from January 1^st^ 2004 to December 31^st^ 2017.

Isolated mycobacteria were Mycobacterium fortuitum (30 patients), Mycobacterium abscessus (8 patients), Mycobacterium mucogenicum (9 patients), Mycobacterium chelonae (6 patients), Mycobacterium peregrinum (4 patients), Mycobacterium porcinum (1 patient), Mycobacterium smegmatis (1 patient) and Mycobacterium arupense (1 patient) ([figure 1](#F1){ref-type="fig"}). One patient had two different NPRGM in two different samples. M. fortuitum was the most frequent isolated mycobacterium, with a sharply increase in 2005, 2007 and 2011. M. abscessus had a significant increase in 2012. M. chelonae was the less isolated mycobacterium with only 0 or 1 isolates per year, except in 2016 when it was isolated three times ([figure 2](#F2){ref-type="fig"}).
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Most of the samples were sputum and other respiratory samples (58 samples) followed by wound exudates and skin biopsies (5 samples), urine (3 samples), blood cultures (2 samples) and several other samples (8 samples).

Clinically significant cases appeared in 12 patients (20.3 %). One patient was classified as doubtful, and the rest of them were non-clinically significant cases. Syndromes and treatment of the patients with true or doubtful clinical significance are shown in [table 1](#T1){ref-type="table"}.

###### 

Characteristics of the cases of infection caused by NPRGM and the case with doubtful significance.

  Case   Year        Sex   Age   Underlying diseases                      Syndrome                         Positive samples       Acid-fast stain   Therapy    Species
  ------ ----------- ----- ----- ---------------------------------------- -------------------------------- ---------------------- ----------------- ---------- ----------------
  1      2004        F     36    Chronic bronchopaty                      Dysphonia                        Laryngeal biopsy       Positive          IS+RI      *M. chelonae*
  2      2005        F     45    NO                                       Mastitis                         Skin exudate           Negative          CI         *M. fortuitum*
  3      2005        M     55    Multiple myeloma                         Catheter infection               Catheter exudate       Positive          AM+CI+CL   *M. chelonae*
  4      2006        F     30    Depressive syndrome                      Skin and soft tissue infection   Skin biopsy            Negative          CI         *M. fortuitum*
  5      2007        F     51    HIV, Burkitt lymphoma                    Disseminated infection           Blood cultures         Negative          CL+CO      *M. fortuitum*
  6      2007        M     48    Multiple myeloma                         Catheter infection               Catheter exudate       Negative          CO         *M. fortuitum*
  7      2008-2013   M     45    HIV, Chronic respiratory insufficiency   Bronchiectasias                  Sputum                 Negative          CL         *M. abscessus*
  8      2011        F     86    Lower eyelid myofibroblastic tumor       Conjunctivitis                   Conjunctival exudate   Not performed     CL         *M. chelonae*
  9      2012-2014   F     56    Chronic obstructive pulmonary disease    Bronchiectasias                  Bronchial lavage       Negative          LE         *M. abscessus*
  10     2012        F     80    NO                                       Arthritis                        Bone prosthesis        Negative          CI+RI      *M. fortuitum*
  11     2012        F     62    Alpha1-antitrypsin deficiency            Bronchiectasias                  Sputum                 Positive          NO         *M. abscessus*
  12     2015        M     71    Chronic obstructive pulmonary disease    Bronchiectasias                  Sputum                 Negative          CI         *M. fortuitum*
  13     2015        F     49    Asthma                                   Bronchiectasias                  Bronchial lavage       Negative          CI+CO      *M. fortuitum*

NPRGM: non-pigmented rapidly growing mycobacteria; M: Male; F: Female; NO: No disease/Not received; AM: Amikacin; CI: Ciprofloxacin; CL: Clarithromycin; CO: Cotrimoxazole; IS: Isoniazid; LE: Levofloxacin; RI: Rifampicin.

The clinical syndromes related to NPRGM include respiratory tract infections (6 cases), catheter infections (2 cases), skin and soft tissue infection (1 case), disseminated infection (1 case), conjunctivitis (1 case), prosthetic joint infection (1 case) and mastitis (1 case).

Regarding the clinical relevance of each species, 50% of the isolates of *M. chelonae*, 37.5% of *M. abscessus* and 23.33% of *M. fortuitum* were clinically significant. None of the isolates of other species were significant.

When we focus on the underlying diseases in the clinically significant group chronic respiratory disease (6 cases), presence of malignancy (2 cases) and human immunodeficiency virus (HIV) disease (2 cases) were detected. There was 1 case of surgical infection related to shoulder prosthesis.

Acid-fast bacilli were detected in stains from samples in 4 of the significant and doubtful cases (33.33%). There was a clinically significant case (conjunctival exudate) in which the acid-fast stain was not performed. Interestingly, 2 samples of the non-significant group were also acid-fast stain positive.

Regarding the therapeutic actions in the clinically significant group, all the patients were treated with antimicrobial therapy except the doubtful case. There were 8 cases treated with monotherapy regimen (3 cases with ciprofloxacin, 2 cases with clarithromycin, 1 case with levofloxacin and 1 case with cotrimoxazol). Ciprofloxacin and clarithromycin were the mainly used antibiotics, either as monotherapy or in a combination antimicrobial regimen. In the implant-related infection it was necessary to remove the prosthesis in order to cure the infection. All the patients were cured, except 2 cases which are currently being under follow-up/control. One patient died due to other pathology. No resistances during therapy were detected.

DISCUSSION {#S4}
==========

NPRGM are usually considered environmental opportunistic pathogens. In our series we documented that only 20.34% of the isolates were clinically significant, compared to 30.8 % in a previous study \[[@ref18]\]. This fact could be related to the increased number of respiratory tract isolates, probably due to the environmental nature of these bacteria. *M. abscessus*, *M. chelonae* and *M. fortuitum* have been usually associated with human diseases, while other members of the group are environmental isolates that cause human infections in rare cases \[[@ref18]-[@ref20]\]. *M. porcinum* has emerged in the last years as a species clearly related to human diseases, being involved in respiratory infections \[[@ref21]\], but our only isolate has no role in the disease of this patient. Among other species, most clinically significant cases of *M. mucogenicum* isolates are involved in catheter-related infections \[[@ref22]\]. *M. peregrinum* is a species included in the *Mycobacterium fortuitum complex*, but only a few cases of true infections have been reported, mainly related to surgical site infections and catheter-related infections \[[@ref23]\]. *M. arupense* isolates have been related to pulmonary disease and osteoarticular infection \[[@ref24]-[@ref25]\]. In our series, all these species appeared to be colonizing organisms or contaminants, while the clinically relevant isolates belonged to the most common pathogens of this group: *M. fortuitum*, *M. abscessus* and *M. chelonae*.

According to the literature, the isolation of NPRGM has not a clear role in respiratory infection diseases such as chronic obstructive pulmonary disease (COPD) and bronchiectasis \[[@ref19]\]. In these patients, the distinction between colonization and infection is a difficult clinical decision in most cases. *M. abscessus* is known to be a pathogen implicated in respiratory syndromes. It account for the majority of pulmonary infection cases in patients with underlying diseases like bronchiectasis, cystic fibrosis or granulomatous diseases like sarcoidosis \[[@ref12], [@ref26]-[@ref28]\]. Twenty eight percent of cystic fibrosis patients are affected by this species, being associated with increased morbidity and mortality, as well as with a rapid decline in lung function. Although it is not an absolute contraindication for lung transplantation, the pulmonary infection is associated with poor prognosis following this procedure \[[@ref13], [@ref27], [@ref29]\].

In our series, most of NPRGM isolations from respiratory samples are not considered to be the major cause implicated in the pathology, but in patients with bronchiectasis, *M. abscessus* was the main isolated pathogen and all cases were treated with monotherapy, except one case that was considered of doubtful significance. This last case had a special clinical situation due to an alpha 1-antitrypsine deficiency, and the isolate was considered colonization because of the lack of symptoms, despite the fact that the organism was isolated from several different samples during a long time period.

The second species more frequently isolated in our series in respiratory samples was *M. fortuitum*. The respiratory infection caused by these mycobacteria is less common than *M. abscessus* disease, but there are cases reported in literature \[[@ref30]-[@ref31]\].

All of the biomaterial-related infections in our series required a combined medical and surgical therapeutic approach. Surgical procedures consisted of implant removal (meshes, catheter, and other prosthesis). *M. fortuitum* was the most frequently isolated mycobacteria from these infections. The ability of rapidly growing mycobacteria to develop biofilms in different surfaces is well known \[[@ref32]-[@ref34]\]. This virulence factor makes almost impossible the eradication of this bacteria using only antimicrobial therapy because of the *in vivo* resistance of sessile organisms against the different antimicrobials \[[@ref35]\], so biofilm removal is mandatory in these cases.

In skin and soft tissue infections *M. fortuitum* was the main etiologic agent in our series. Acupuncture, infected surgical equipment or tattoos have been established as risk factors to develop a NPRGM skin infection \[[@ref36]-[@ref37]\]. The water used in the sterilising processes seems to be the main source of contamination in many cases. Monotherapy regimen was the selected treatment in all cases for these infections.

Due to the fact that NPRGM are resistant to conventional antituberculous drugs, the treatment has to be directed through *in vitro* susceptibility testing \[[@ref16]\], being clarithromycin and ciprofloxacin the most frequently selected antibiotics \[[@ref38]\]. Despite the previously described development of resistance during monotherapy \[[@ref39]\], we have not detected any case of such problem, probably due to the low bacterial load presented in most of the cases, which minimises the probability of selection of resistant mutants.

In conclusion, the major difficulty to evaluate the clinical significance of NPGRM resides in the fact that most of these isolates are regarded as a contamination. However, we observed in our series that the isolation of a specific NPGRM (*M. abscessus, M. fortuitum* and *M. chelonae)*, or in specific samples (respiratory samples, skin, soft tissue, and biomaterials) is almost always related to the clinical syndrome. In order to avoid the failure of the treatment, an adequate microbiological identification and susceptibility test is needed, which would allow to choose a correct antimicrobial therapy and management of patients.
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